Chem. J. Chinese Universities ›› 2021, Vol. 42 ›› Issue (11): 3367.doi: 10.7503/cjcu20210460

• Review • Previous Articles     Next Articles

Investigations upon the Bioconjugation-based Construction Technologies and Applications of Aptamer-drug Conjugates

ZHAO Zhuo, WANG Xueqiang()   

  1. Molecular Science and Biomedicine Laboratory (MBL),State Key Laboratory of Chemo/Biosensing and Chemometrics,College of Chemistry and Chemical Engineering,Hunan University,Changsha 410082,China
  • Received:2021-07-01 Online:2021-11-10 Published:2021-09-10
  • Contact: WANG Xueqiang E-mail:wangxq@hnu.edu.cn
  • Supported by:
    the National Key Research and Development Program of China(2018YFA0902300);the Huxiang Young Talent Program from Hunan Procince, China(2019RS2022)

Abstract:

Aptamers are called “chemical antibodies” and have similar or superior specificity and affinity as antibodies. And it can precisely target the target protein and specifically bind to the target protein. In addition, aptamers possess many advantages such as simple acquisition and synthesis, easy chemical modification, not easy to denature, a wide range of targets, low immunogenicity, and fast cell internalization. Therefore, aptamers have been widely utilized in various research fields. In the area of cancer therapy, aptamers, as an excellent target identification tool and drug delivery vehicle, can precisely deliver anticancer drugs to tumor tissues. By coupling the nucleic acid aptamer to the drug molecule, we can make the drug molecule enter the targeted cells along with the aptamer through the targeting effect of the aptamer, so as to achieve the enrichment of the drug molecule in the targeted cells, and then produce the growth inhibitory effect on the targeted cells. In recent years, aptamer-drug conjugates have evolved into a frontier emerging field of cancer targeted therapy. It is hoped that through the study of nucleic acid aptamer conjugated drugs, new perspectives in targeted cancer treatment will be provided. This article reviewed the studies on aptamer-drug conjugates constructed by bioconjugation technologies and their applications.

Key words: Aptamers-drug conjugate, Targeted therapy, Cancer

CLC Number: 

TrendMD: